

# Alona Zer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/764504/alona-zer-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

1,532  
citations

16  
h-index

39  
g-index

56  
ext. papers

2,269  
ext. citations

4.1  
avg, IF

4.58  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 53 | Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 110-110   | 2.2  |           |
| 52 | ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.. <i>Oncologist</i> , <b>2022</b> , 27, e76-e84  | 5.7  | 0         |
| 51 | Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.. <i>Neuro-Oncology Advances</i> , <b>2022</b> , 4, vdab188  | 0.9  | 2         |
| 50 | The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 1178-1184  | 4.5  | 1         |
| 49 | Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1250-1258  | 15.4 | 12        |
| 48 | Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e15579-e15579  | 2.2  | 0         |
| 47 | Integration of proteomic and clinical data for the prediction of response to immune checkpoint inhibitor therapy in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21110-e21110  | 2.2  |           |
| 46 | Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9023-9023 | 2.2  |           |
| 45 | A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS3142-TPS3142             | 2.2  | 1         |
| 44 | Abdominal desmoid- course, unique genetic background, and severe outcomes in a large local series.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e23544-e23544   | 2.2  |           |
| 43 | Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2021</b> , 17, e125-e131  | 1.9  | 0         |
| 42 | Long term follow-up of EGFR mutated NSCLC cases. <i>Translational Oncology</i> , <b>2021</b> , 14, 100934   | 4.9  | 2         |
| 41 | Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1183-1191   | 7.5  |           |
| 40 | The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , <b>2021</b> , 99, 555-561   | 3.6  | 2         |
| 39 | Sarcoma incidence and subtype distribution in Israel - A population-based study. <i>Cancer Epidemiology</i> , <b>2021</b> , 70, 101876  | 2.8  | 0         |
| 38 | Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung <b>2021</b> , 9,   |      | 7         |
| 37 | BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 603223  | 5.3  | 3         |

|    |  |      |     |
|----|--|------|-----|
| 36 | Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1133-1140  | 13.4 | 96  |
| 35 | Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥0%: real-world data. <i>OncoImmunology</i> , <b>2021</b> , 10, 1865653   | 7.2  | 6   |
| 34 | Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2331-2334  | 3.2  | 2   |
| 33 | Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. <i>Immunotherapy</i> , <b>2020</b> , 12, 235-243   | 3.8  | 7   |
| 32 | Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). <i>Lung Cancer</i> , <b>2020</b> , 143, 40-46  | 5.9  | 20  |
| 31 | BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii1-ii1   | 1    |     |
| 30 | Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant. <i>Radiology and Oncology</i> , <b>2020</b> , 54, 227-232  | 3.8  | 1   |
| 29 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 618-627   | 8.9  | 116 |
| 28 | Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. <i>Journal of Global Oncology</i> , <b>2019</b> , 5, 1-8  | 2.6  | 9   |
| 27 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 924-937 | 21.7 | 562 |
| 26 | Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 278-286.e14-9  |      | 5   |
| 25 | Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. <i>Oncology Research and Treatment</i> , <b>2019</b> , 42, 275-282  | 2.8  | 6   |
| 24 | A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 11064-11064  | 2.2  | 3   |
| 23 | Primary cardiac sarcomas: A multi-national retrospective review. <i>Cancer Medicine</i> , <b>2019</b> , 8, 104-110   | 4.8  | 21  |
| 22 | Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis. <i>European Journal of Cancer Care</i> , <b>2019</b> , 28, e12909   | 2.4  | 24  |
| 21 | Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 63, 71-78  | 14.4 | 14  |
| 20 | Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , <b>2018</b> , 126, 217-223  | 5.9  | 67  |
| 19 | BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1128-1137  | 8.9  | 84  |

|    |  |     |     |
|----|--|-----|-----|
| 18 | High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer. <i>Oncology</i> , <b>2018</b> , 95, 13-19   | 3.6 | 5   |
| 17 | Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). <i>Lung Cancer</i> , <b>2018</b> , 124, 117-124  | 5.9 | 19  |
| 16 | Neutrophils to lymphocytes ratio and platelets to lymphocytes ratio in pregnancy: A population study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196706   | 3.7 | 11  |
| 15 | Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8506-8506  | 2.2 | 100 |
| 14 | Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9076-9076 | 2.2 |     |
| 13 | The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1705-1716   | 8.9 | 25  |
| 12 | Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 426-434.e1               | 4.9 | 64  |
| 11 | Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2018</b> , 144, 71-79  | 3.9 | 22  |
| 10 | ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 156-161  | 4.9 | 56  |
| 9  | A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,                                   | 9.7 | 48  |
| 8  | Response to Yamamoto et al. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, e129-30  | 8.9 |     |
| 7  | Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <i>Lung Cancer</i> , <b>2016</b> , 98, 114-117  | 5.9 | 99  |
| 6  | Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e107273                         | 3.7 | 7   |
| 5  | Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19111-e19111†.2                       | 2.2 |     |
| 4  | Collaterals. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 662-3  | 8.9 |     |
| 3  | Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study. <i>Chemotherapy</i> , <b>2012</b> , 58, 95-101  | 3.2 | 1   |
| 2  | Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (GCSF) on days 8 and 12 in breast cancer patients: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 202-202      | 2.2 |     |
| 1  | Cardiac mass in a rapidly deteriorating patient. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e656-8  | 2.2 | 2   |

